PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.
Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
A user is experimenting with a homemade solution of WAY-316606 for hair regrowth, combining it with other treatments like minoxidil and dutasteride. The community expresses concern over the safety and mental health implications of such drastic measures, with mixed opinions on the effectiveness of WAY-316606.
The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.
Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.
GHK-Cu serums for hair growth have mixed results, with some users not seeing significant benefits. Users have tried various brands like Tricomin and Actifolic without success.
Hair loss discussion focused on 2% Fluridil's peak efficacy at 3 months and 7% Fluridil group buy results, including shedding decrease, side effects, and regrowth.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.